Compound handling is a fundamental and critical step in compound screening throughout the drug discovery process. Although most compound-handling processes within compound management facilities use 100% DMSO solvent, conventional methods of manual or robotic liquid-handling systems in screening workflows often perform dilutions in aqueous solutions to maintain solvent tolerance of the biological assay. However, the use of aqueous media in these applications can lead to suboptimal data quality due to compound carryover or precipitation during the dilution steps. In cell-based assays, this effect is worsened by the unpredictable physical characteristics of compounds and the low DMSO tolerance within the assay. In some cases, the conventional approaches using manual or automated liquid handling resulted in variable IC 50 dose responses. This study examines the cause of this variability and evaluates the accuracy of screening data in these case studies. A number of liquid-handling options have been explored to address the issues and establish a generic compound-handling workflow to support cell-based screening across our screening functions. The authors discuss the validation of the Labcyte Echo reformatter as an effective noncontact solution for generic compound-handling applications against diverse compound classes using triple-quad liquid chromatography/mass spectrometry. The successful validation and implementation challenges of this technology for direct dosing onto cells in cell-based screening is discussed. (Journal of Biomolecular Screening 2009:452-459) 
INTRODUCTION
T est compounds being evaluated in project screening assays cover a diverse spectrum of chemical classes with a broad range of physical properties. These properties, including solubility and hydrophobicity, have caused a varying degree of compound loss or carryover in conventional manual and semiautomated compound-handling workflows, resulting in deviation from intended test concentration, poor data consistency, and poor correlation with downstream assays. These effects are exacerbated in cell-based screening due to the low DMSO tolerance in these assays. As a consequence, these issues give rise to inaccurate compound IC 50 values in these in vitro screens, potentially misdirecting chemistry structure-activity relationship (SAR) analysis and affecting dose selection for in vivo and safety assessment determination. Compound-handling issues have been scrutinized only recently as a result of improved analytical technologies across the pharmaceutical industry and are being addressed actively. Spicer et al. 1 have demonstrated that false-negative screening data will increase in cases where the dilution process contains aqueous serial dilutions. This is due to adsorption of compound onto plates and pipette tips and can also be caused by compound precipitating from solution. This results in a lower than expected concentration of compound within the assay and leads to a higher IC 50 result. Similarly, factors that contribute to a higher than expected concentration of compound will increase the apparent potency of the test compound.
In routine cell-based screening, compounds are typically serially diluted using a variety of processes before being added to microplates that contain the cell monolayer. IC 50 data are generated from the endpoint measurements across the doseresponse curves. In many cell-based assays, both manual and automated, the serial dilution is often conducted in aqueous culture media owing to low solvent tolerance. This exacerbates the problems of handling compounds with physical properties of typically high LogD values and low solubility. Under these conditions, interaction between compound and surfaces such as that of microplates and pipette tips may result in loss of compound or carryover. In addition, poor compound solubility can also lead to compound precipitation in situ and contribute to further deviation from the intended test concentration for the compound.
In this report, we present key data from case studies to illustrate the compound-handling issues that compound screening faces routinely. In these studies, high-performance liquid chromatography coupled to triple-quad mass spectrometry (HPLC-MSMS) was used to directly quantify the actual compound concentration without using surrogate endpoint measurements.
In recent years, different workflow and/or automation solutions have been implemented across drug discovery in an attempt to address the compound-handling issues in compound management as well as in screening functions. One such major technological advance is acoustic droplet ejection (ADE) technology. This new platform uses acoustic energy to precisely and accurately transfer multiples of nanoliter-size droplets from source plate to destination plate. 2 This noncontact "ondemand" technology provides an enabling platform to prepare dose-response series directly in the destination plate, which results in an improvement in IC 50 analyses when applied to compound screening. 3 The dispensing precision of the Echo 550 (Labcyte, Sunnyvale, CA) has been shown to be typically less than 2% using fluorescein in DMSO, 4 and the application in miniaturizing high-throughput dose-response assays has already been documented, 5 with better performance at low dispensing ranges than other nanoliter dispensing methods. 6 Within the Cancer Bioscience department in AstraZeneca UK, we have performed an in-depth validation of the Echo 550 ADE reformatter and fully implemented this technology on all routine cell-based screening.
MATERIALS AND METHODS

Preparation of rhodamine standard solution
The fluorescent dye rhodamine was selected as the standard dye in this study instead of fluorescein because of its ability to maintain high fluorescence in DMSO. Rhodamine was dissolved in 100% DMSO to a concentration of 100 µM and stored at room temperature in an amber vial. The solution was further diluted to 1 µM in DMSO prior to use.
HPLC-MSMS
All analysis for the determination of compound concentrations in the manual dilutions and Echo validation was conducted using a Waters Micromass Ultima (Waters, Milford, MA), linked to an Agilent 1100 series HPLC system (Agilent, Santa Clara, CA). A CTC HTS PAL autosampler was used for the injection of samples, and chromatography was conducted on a Phenomenex MAX-RP 50 × 2.1 column (Phenomenex, Torrance, CA) at 50 °C using a water/methanol 10-mM ammonium acetate gradient.
Test compounds
All compounds were dissolved in 100% DMSO as 10-mM stock solutions and stored under nitrogen before use in all subsequent experiments.
Manual dilution series
To initiate the compound dilution series, we diluted the compound stock solution in culture media to a final concentration of 3 µM. This solution was further serially diluted to generate a dilution series of 11 concentrations from 1 µM to 0.05 nM without changing the disposable pipetting tips. This process was repeated with a tip change between each step of the serial dilution to generate a second dilution series. The lowest 8 concentrations of both dilution series were analyzed alongside a standard curve. The standard curve was prepared by serially diluting the same 10-mM stock 10-fold in methanol to generate 4 methanolic stocks from 100 µg/mL down to 0.1 µg/mL. These were used to spike fresh culture media, to generate a standard curve with a concentration range covering the 8 concentrations of the manual dilutions.
Echo 550 control files
All Echo dispensations were performed with text files in "comma-separated value" format using the Labcyte cherrypicking software instead of the default interface program. This software allows full control of source-to-destination transfer patterns and creates multiple dilution series in the destination plate.
Echo source plate and compound predilution
All Echo ADE transfers were performed with Labcytecertified 384-well polypropylene plates. For dose-response studies, 40 µL DMSO stock solution of each compound was placed in the corresponding first quadrant well (i.e., A1, A3 . . . C1, C3, etc.) in the 384-well Labcyte source plate. Each source plate contained a maximum of 84 compounds (i.e., row O empty). A Matrix Hydra automated liquid handler (Matrix Technologies, Hudson, NH) fitted with 100 µL syringe was used to produce three 100-fold serial dilutions of the 10-mM stock in the corresponding second, third, and fourth quadrants with thorough mixing and extensive DMSO washes between each dilution step. This resulted in 4 concentrations of each compound in DMSO at 10 mM, 100 µM, 1 µM, and 10 nM. All source plates were centrifuged at 1000 g for 5 min after the predilution process.
Echo 550 linearity determinations
A Labcyte-certified source plate containing 40 µL of 10 nM rhodamine was used for linearity determinations. Multiples of 2.5-nL droplets were dispensed into a series of wells in the 384-well destination plate to achieve between 2.5 and 100 nL total dispensed volume per well. All wells were backfilled with DMSO on the Echo 550 to 100 nL final volume. Then, 40 µL of phosphate-buffered saline (PBS) was added to each well and the relative fluorescence measured on a Tecan Ultra Multimode plate reader (Tecan, Männedorf, Switzerland).
Echo validation by HPLC-MSMS
For the validation of the Echo acoustic dispensing, a series of 105 compounds was selected. These compounds included project compounds and a selection of problematic compounds with a broad range of physical properties: clogP (-1.35 to 10.97), aqueous solubility (0.05 to 83 µM), and molecular weight (RMM 247 to 695). The Echo was used to acoustically dispense multiples of 2.5-µL droplets of the DMSO working solutions into dry wells of the destination plate, creating a 7-point concentration series of 0.3, 1, 3, 10, 30, 100, and 300 nM in a final equivalent volume of 300 µL. All destination wells were backfilled to a final 120-nL DMSO equivalent within the acoustic transfer step. All wells were then solubilized in 300 µL of 50% methanol in water and analyzed against a standard curve using HPLC-MSMS.
A standard curve was prepared using the same 10-mM stock from the source plate preparation procedure. A series of DMSO working solutions were prepared, by first diluting the 10-mM stock 5-fold to 2 mM and then a serial dilution of five 10-fold steps down to 0.02 µM. The working solutions were used to spike a standard curve in 50% methanol in water to the same 7-point concentration series as generated by the Echo.
Echo dosing in protein kinase cell-based assay
MDA-MB-468 human breast adenocarcinoma cell line was obtained from ATCC (no. HT-138; ATCC, Manassas, VA) and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and 1% glutamine.
These cells were plated in a 96-well Corning (Corning, NY) tissue culture-treated plate at 4000 cells/well in 100 µL. The cells were incubated for 24 h prior to compound dosing using workflow, as illustrated in Figure 1 . All compounds were prepared as described above in the Labcyte-certified source plate. Prior to Echo dosing, 70 µL of the culture medium was aspirated with a 96-channel Apricot Personal Pipettor (PerkinElmer, Waltham, MA). The cell plate with remaining volume was loaded into the Echo, and compound transfer was carried out as described above. After completion, the plate was loaded onto the personal pipettor, and the 70 µL of culture medium was returned to the corresponding well. The plate was further incubated for 2 h, and 20 µL of 20% formaldehyde in PBS was added for the fixation of the cell monolayer.
To measure the reduction of intrinsic kinase activity by compound treatment, we washed the fixed cell plate 3 times with PBS/0.05% Tween-20 (PBST) followed by overnight incubation with 60 µL of a primary antibody solution containing a phosphospecific antibody for AKT protein kinase. The cell plate was washed again with PBST and incubated for 1 h with 60 µL of a solution containing an Alexa Fluor  488-labeled goat-antirabbit secondary antibody (Molecular Probes, Carlsbad, CA). The plate was washed with PBST, and 50 µL of PBS was added prior to imaging on an Acumen Explorer cytometer (TTP LabTech, Royston, UK).
Cell monolayer staining and visualization
The fixed cell plate was washed 3 times with PBST solution. Then, 100 µL of PBS containing 0.1% propidium iodide (PI) solution was added to stain the nucleus of the fixed cells, and the resultant stained cell monolayer was imaged on an Acumen Explorer cytometer.
RESULTS
Manual dilution series
This study was initiated when excessive data variation and poor IC 50 correlation were observed between assays within the screening cascade of several projects. Projects were apparently more vulnerable to this variability when their key compound series suffered from high hydrophobicity and/or low solubility. Although the screening operators followed established standard operating procedures, widely variable IC 50 values were observed for certain compound chemical series between experienced operators. In a cross-functional collaborative attempt to dissect the root source of the variability, the compound-handling workflow of these projects was investigated with the output analyzed directly by triple-quad liquid chromatography/mass spectrometry (LC/MS) to quantify the exact amount of the compounds transferred into the final assay well and then compared with that expected.
The conventional method for the manual generation of compound serial dilutions prior to use in a cell-based assay did not involve changing tips as the compound was diluted between wells to give improved throughput. As can be seen in Figure 2 , this workflow resulted in significant carryover of compound in this particular assay. In contrast, the dilution series that incorporated a tip change between the dilution steps is clearly not as susceptible to carryover. However, the introduction of additional clean plastic surfaces through tip changes has resulted in general loss of compounds throughout the process when compared with the expected concentration.
This clearly illustrates that with contact liquid handling, it is very difficult to achieve accurate compound dosing into cellbased assays with or without tip changes. Although noncontact nanoliter dispensers were available, the working principle of these dispensers still resulted in direct compound interaction with their corresponding aspirate/dispense mechanism.
Echo 550 validation
The Labcyte-focused acoustic reformatter is the first instrument that provides true noncontact dispensing directly from source to destination well. With the broad, dynamic handling range required for IC 50 generation, the dispense linearity was evaluated on the Labcyte Echo 550 reformatter (Fig. 3) . Using rhodamine in DMSO from the source plate, the Echo 550 was capable of delivering multiples of 2.5-nL droplets to each well with good precision from 2.5 nL up to 100 nL. Although the Echo reformatter has been confirmed to deliver high-precision DMSO transfers, it remained unclear whether different compounds affect the fluid dynamic and surface tension of the stock solution and have a detrimental effect on the precision of the acoustic transfer to the destination well. To evaluate the potential effect of a compound's physicochemical properties on Echo performance, we chose 105 compounds to cover a wide range of LogD and solubility values for evaluation of acoustic "on-the-fly" IC 50 generation by triple-quad LC/MS.
In general, across the 105 compounds, there is good agreement between intended and measured concentrations. Representative results for the LC/MS data on 2 of the 105 compounds are shown in Figure 4 . Overall, replicates are reproducible within a run. However, although measured concentrations for the concentration range 3 to 300 nM tend to agree quite closely with intended concentrations, at the lower concentrations (0.3 nM and 1nM intended), the measured concentrations are more variable for many compounds, and on average, the measured concentration is slightly larger than intended. The geomean ratios (measured/ intended) are 1.24 and 1.13, respectively. It is likely that the observed bias at the lowest 2 concentrations is attributable to the analytical method. The measurements of some of these lowconcentration samples were near the analytical detection limit of the mass spectrometry instrumentation; this typically leads to a higher variation of the detection signal. Nevertheless, the results indicate that the Echo reformatter is suitable for the acoustic delivery of compound in cell-based screening.
Echo performance in cell-based assays
To further validate the Echo reformatter platform in doseresponse studies, we undertook pilot assays to validate the performance of this technology platform on several cell-based assays. The dose-response curve illustrated in Figure 5 was generated by dispensing compound directly onto monolayers of adherent MDA-MB-468 human breast tumor cells. The IC 50 curves exhibited normal sigmoidal characteristics with Hill coefficients close to unity. Although the phospho AKT kinase cell-based assay used the laser-line cytometric imaging analysis endpoint, the replicates for each concentration point were consistent.
Despite excellent IC 50 correlations in pilot studies, significant variability within screening assays was observed during early implementation of the acoustic platform. It was apparent that these reports of result variability arose consistently within the same assays. To identify the source of variation, we validated the performance of the Echo and studied the images from the Acumen laser cytometer. The variable data often correlated to test wells that had reduced antibody-binding signal, especially at the center of the well. PI nuclear staining was performed on this cell monolayer and led to the discovery of damage in the fixed cell monolayer. Root cause analysis has indicated that the monolayer damage occurred during the compound transfer by the Echo reformatter, as illustrated in Figure 6 .
Different approaches to the delivery of compound to cell monolayers have been explored using the Echo reformatter. As shown in Figure 6a , damage to the monolayer is clearly visible as a result of DMSO dispensation to the center of the well. The effect was reduced if the dispensed volume was spread across the monolayer (Fig. 6b) , although damage remained visible. The damage mediated by the DMSO dispense was eliminated by the offset of the transfer position to between 0.5 and 1.0 mm from the wall of the well (Fig. 6c) to ensure that the droplets reached the bottom of the target well. The deeper meniscus of the culture media at the edge of the well assists in preventing the multiple DMSO droplets from reaching the cell monolayer and hence protects the monolayer from damage. This offset configuration has been adopted as a default setting for all 96-well-based cell-based assays on the acoustic reformatter.
In an extended study, a compound set containing 18 test compounds was evaluated in the same assay to determine interday variability using the Echo for compound delivery. The results are summarized in Figure 7 . Each compound was tested between 6 and 10 times on different occasions in duplicate, and the results indicated a good level of consistency between IC 50 values obtained for a given compound. Based on these data, if a typical compound is tested 3 times, the approximate confidence interval ratio is 1.63. These results further confirm the quality performance and robustness of the Echo reformatter platform in IC 50 generation.
DISCUSSION
In recent years, with the development of high-throughput screening (HTS), compound handling has been moved to center stage. Much emphasis has been placed on the throughput and liquid-handling precision of these processes. It is recognized that compound-handling issues such as carryover or solubility in the compound management workflow would potentially undermine the quality of the screening data, and different solutions have been deployed to address this risk. Downstream secondary screening workflows are equally at risk. Manual compound workflows were developed with or without pipetting tip changes during the typical serial dilution steps to increase throughput or avoid carryover. However, the results indicated that, with some compounds, neither approach would yield a precise dilution series because of the physical properties of these compounds. Similar observations were made with automated liquid handlers where both approaches have also proved to be ineffective. Poor aqueous solubility also has a detrimental effect on any compound handling that involves a low solvent composition in the dilution stages. All of these effects result in increased risk in the drug discovery process due to the lack of reproducibility of IC 50 data between assays and poor correlation with downstream processes within the project screening cascade. Another effect is a poor SAR for these compound classes, and inaccurate IC 50 data potentially misguide the choice of a compound dosing regime for downstream in vivo testing or safety interpretation during preclinical evaluation.
Advances in analytical instrumentation have enabled quantitative evaluation of compound handling in drug discovery activities. We were able to optimize the manual compoundhandling workflow by maintaining compounds in 100% DMSO throughout most of the dilution steps. In this approach, the final culture media dilution step was undertaken such that the resulting solution is dosed onto cells within 15 min of the start of the dilution process to minimize compound adherence to the intermediate dilution plates or tips. This approach was found to perform satisfactorily, but this method limits the assay throughput in both the manual and automated liquid-handling process because of the time constraint.
The introduction of ADE technology has proven to be revolutionary and timely to address the challenges in compound-handling workflow. The Echo reformatter from Labcyte now enables, for the first time, a direct transfer of DMSO-based reagents from a certified source plate to a destination plate in a true noncontact manner. This represents a major scientific breakthrough in the liquid-handling field and provides a "zero carryover" capability for compound-handling applications. To deploy this technology in secondary screening, we have developed a workflow and a standardized layout of the source plate such that the Echo reformatter can perform "on-the-fly" IC 50 generation without reloading the source plate. This requires the reformatter to cover a wide dynamic volume range. As can be seen from Figure 3 , the Echo reformatter is capable of delivering DMSO-based solutions with excellent linearity. This ability will greatly facilitate IC 50 generation in biochemical screening with less susceptibility to issues arising in the generation of intermediate dilutions.
The lack of experience of this new technology in cell-based screening applications during this early evaluation phase meant that most of the configuration and workflow had to be developed from basic principles. With the destination plate in an upside-down position during the acoustic transfer operation, stringent validation was required to pinpoint the optimum volume of culture media remaining in the well prior to the acoustic transfer process. A 30-µL volume of culture media is retained in the well during the compound transfer process to protect the cell monolayer from direct interaction with the DMSO compound droplets. This volume has also been optimized to be of insufficient weight/volume to fall out due to gravity. Further challenges were encountered when the implementation of this technology was broadened to other screening projects. The observation of cell monolayer damage by the Echo dispensing was a surprise, and this has further indicated the steep learning curve in implementing such a new technology to screening. Although the remaining volume of 30-µL culture medium represents a significant liquid column above the cell monolayer, the change in shape of the meniscus when the destination plate was inverted caused the thinning of the liquid at the center of the well, leading to direct exposure of the cell monolayer to the DMSO droplets during the acoustic transfer. This effect was eliminated when the path of the droplets was guided toward the wall of the plate wells such that the droplets were prevented from hitting the monolayer by dispensing to the larger volume at the edge of the meniscus. Fluorescence imaging has shown that the pooled droplets collected and concentrated around the slope of the meniscus. This has the additional advantage that the droplets do not diffuse and mix with the media until the cell plate is returned to the normal position. The turning motion helps the mixing of the samples through the change in the meniscus and synchronizes the start of the compound treatment across the plate. The addition of the remaining volume of media also has the effect of mixing the compound in media prior to incubation. A similar effect was seen when the Echo reformatter was used to carry out compound dosing to 384-well plates. With the geometry of the well in this format, we have demonstrated that no culture media are required to be removed from the typical culture volume (40 µL) prior to the Echo transfer.
The introduction of ADE in IC 50 generation represents a major advance in cell-based secondary screening. The use of acoustic reformatting technology, coupled with improvements in compound integrity within our compound management capability, will ensure that the intended quantity of compound will be delivered to the destination well with a high degree of reproducibility. This is the first time in the past few decades of microplate-based screening that screening data would be able to correlate to the intended test concentration with high confidence.
The recognition of complex compound interactions with surfaces has raised further questions about the integrity of the observed IC 50 in different assays. Although the precise quantity of test compound can now be delivered into the test well directly, through the use of the acoustic transfer technology, it is still not possible to control the partitioning of the test compounds to other surfaces within the well or to guarantee compound solubility. These effects reduce the availability of the compound to interact with the intended drug target within the assay well. Technology has advanced to enable confidence in compound delivery to the assay well, but as with any method, the effect of poor aqueous solubility or adsorption/partitioning to surfaces within the biological assay will still have an impact on HTS and accurate potency determination. 7 
CONCLUSION
In summary, the introduction of the Echo acoustic reformatter has represented a major milestone in pharmaceutical screening applications. It has revolutionized the compound management process to support HTS and biochemical screening workflow. In this report, we have demonstrated the broad utility of this technology across cell-based screening. In Alderley Park Cancer Bioscience, the Echo acoustic transfer technology has been adopted as the default workflow for all cell-based screening campaigns, replacing manual processes and conventional liquid handlers. This has led to an overall increase in data quality and correlation between cross-project and downstream assays.
The future should see this technology become more costeffective, enabling a broader utilization across the scientific community. With the increase in validated applications and market demand, there are now other manufacturers of ADE technology in the market. This competition will increase the versatility of the instruments using the acoustic ejection technology as well as facilitate the availability of more affordable platforms.
